Skip to main content
. 2011 Feb 28;108(11):4465–4470. doi: 10.1073/pnas.1019020108

Fig. 5.

Fig. 5.

VP-delivered pHSVsiLA1 inhibits binge alcohol drinking unrelated to TLR4. (A) Binge alcohol responding in P rats on an FR-4 schedule during the presurgery (5 d), and after pHSVsiLA1 infusion into the VP. The asterisk represents significance for pHSVsiLA1 compared with PBS and the presurgery control using the Tukey and Dunnett's test, respectively, following significant group [F(1, 12) = 50.31, P < 0.0001] and session [F(12, 182) = 3.151, P < 0.0004] effects. (B) Binge alcohol responding in P rats on an FR-4 schedule for presurgery (5 d), and after pHSVsiNC or PBS microinfused into the VP. Both displayed a similar profile of effects (P > 0.05). (C and D) Cohorts of P rats trained to binge on alcohol were microinfused with pHSVsiNC or pHSVsiLA1 into the VP and tissues collected at 72 h (C) or 15 d (D) were immunoblotted with antibodies to α1, α2, CCR2, or TLR4 using GAPDH as loading control. Results are densitometric units ± SEM. pHSVsiLA1 inhibited α1 at day 3 (P < 0.05), but not 15 d postinfusion (P > 0.05). Expression of α2, CCR2, and TLR4 was not inhibited (P > 0.05). (See SI Materials and Methods for blood alcohol levels and additional statistical details for A–D.)